Actively Recruiting
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
Led by Astellas Pharma Korea, Inc. · Updated on 2026-03-11
377
Participants Needed
13
Research Sites
277 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is for people in South Korea who have cancer in or around the stomach (gastric cancer) or cancer where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Their cancer is locally advanced, unresectable, or metastatic. Locally advanced means the cancer has spread to tissue close by. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. In South Korea, VYLOY is approved for the treatment of gastric cancer or GEJ cancer. The people in this study will receive VYLOY as part of their usual treatment for their cancer. In standard clinical practice VYLOY is given to people slowly through a tube into a vein. The main aim of the study is to collect information in a real-world setting about the safety of VYLOY in people with gastric cancer or GEJ cancer in clinics in South Korea. This study will also help researchers learn how long people's gastric cancer or GEJ cancer stays stable. This study is about collecting information only. This is known as an observational study. The individual's doctor decides on treatment, not the sponsor (Astellas). The study will last about 1 year (54 weeks).
CONDITIONS
Official Title
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients who receive treatment with VYLOY injection, according to the approved local label.
You will not qualify if you...
- Patients with any contraindication for VYLOY injection, according to the approved local label.
- Patients who are registered or scheduled to be registered in any clinical trials involving investigational drug administration.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 13 locations
1
KR82010
Goyang-si, Gyeonggi-do, South Korea
Actively Recruiting
2
KR82008
Suwon, Gyeonggi-do, South Korea
Actively Recruiting
3
KR82009
Suwon, Gyeonggi-do, South Korea
Actively Recruiting
4
KR82006
Yangsan, Gyeongsangnam-do, South Korea
Actively Recruiting
5
KR82012
Hwasun Gun, Jeollanam-do, South Korea
Actively Recruiting
6
KR82001
Seoul, South Korea
Actively Recruiting
7
KR82002
Seoul, South Korea
Actively Recruiting
8
KR82003
Seoul, South Korea
Actively Recruiting
9
KR82004
Seoul, South Korea
Actively Recruiting
10
KR82005
Seoul, South Korea
Actively Recruiting
11
KR82007
Seoul, South Korea
Actively Recruiting
12
KR82011
Seoul, South Korea
Actively Recruiting
13
KR82013
Seoul, South Korea
Actively Recruiting
Research Team
A
Astellas Pharma Global Development, Inc.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here